New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
07:13 EDTVVUS, AUXLVIVUS and Auxilium announces FDA accepted STENDRA's supplemental application
VIVUS (VVUS) and Auxilium Pharmaceuticals (AUXL) announced that the FDA has accepted a supplemental application that proposes to revise the STENDRA, or avanafil, prescribing information with efficacy and safety information from Study TA-501, entitled "A Randomized, Double-Blind, Placebo-Controlled Evaluation of Avanafil for On-Demand Treatment of Men with Erectile Dysfunction." The PDUFA date for the supplemental filing is September 20.
News For VVUS;AUXL From The Last 14 Days
Check below for free stories on VVUS;AUXL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 17, 2014
07:39 EDTAUXLEndo deal for Auxilium highly complimentary, says UBS
Subscribe for More Information
07:15 EDTAUXLEndo bid for Auxilium positive, says Wells Fargo
Subscribe for More Information
07:14 EDTAUXLAuxilium to 'carefully review' proposal from Endo for $28.10 per share
Subscribe for More Information
07:12 EDTAUXLQLT Inc. provides update on merger with Auxilium
QLT Inc. (QLTI) announces that it has been advised by Auxilium Pharmaceuticals (AUXL) that Auxilium has received an unsolicited offer from Endo International (ENDP) to acquire all of the issued and outstanding shares of Auxilium. Auxilium has further advised QLT that the board of Auxilium is reviewing the Endo Proposal, and has not withdrawn, modified, withheld, changed or qualified its recommendation with respect to the proposed merger with QLT pursuant to the Agreement and Plan of Merger among QLT, Auxilium, QLT Holding, and QLT Acquisition, dated June 25. The Merger Agreement continues in full force and effect. In accordance with the Merger Agreement, QLT has consented to the adoption by Auxilium of a stockholder rights plan in response to the Endo Proposal.
07:11 EDTAUXLAnalysts say Auxilium QLT deal could be snarled by Endo bid, Reuters says
Subscribe for More Information
07:04 EDTAUXLAuxilium could be worth $34-$45/share in takeout, says Jefferies
Jefferies believes Auxilium (AUXL) could be worth more than the $28.10 per share offer by Endo (ENDP). The firm says it can get to valuations of $34-$45 per share for Auxilium under a takeout scenario. Jefferies thinks proposed acquisition cost "leaves considerable value on the table." It keeps a Buy rating on Auxilium with a $34 price target. In pre-open trading, Auxilium is trading well above Endo's offer price at $30.26 per share, up 41% or $8.74.
06:36 EDTAUXLEndo volatility expected to move on Endo acquisition proposal
Subscribe for More Information
06:25 EDTAUXLAuxilium volatility expected to move on Endo acquisition proposal
Subscribe for More Information
September 16, 2014
17:29 EDTAUXLAuxilium up 42% following Endo acquisition proposal
16:48 EDTAUXLEndo delivers proposal to acquire Auxilium for $28.10 per share in cash, stock
Subscribe for More Information
16:48 EDTAUXLEndo delivers proposal to acquire Auxilium for $2.2B in cash, stock
Subscribe for More Information
September 14, 2014
13:51 EDTAUXLAuxilium looks like 'overpriced tax shelter', Barron's says
Auxilium's (AUXL) acquisition of QLT (QLTI) for tax inversion purposes followed a collapse in Testim sales and the company "seems like an overpriced tax shelter," Barron's argues in a follow up article. Reference Link
September 12, 2014
11:59 EDTAUXLAuxilium management to meet with Jefferies
Subscribe for More Information
September 11, 2014
12:42 EDTVVUSOrexigen falls after FDA requires warnings on Contrave label
Subscribe for More Information
10:59 EDTVVUSArena competition picks up after Contrave approval, says Piper Jaffray
Subscribe for More Information
08:01 EDTVVUSOrexigen Contrave could have stronger launch than peers, says Wells Fargo
After the FDA approved Orexigen's (OREX) Contrave as a treatment option for chronic weight management, Wells Fargo does not believe the label included any significant surprises. The firm thinks multiple factors increase the chances that Contrave's launch will be stronger than two other weight loss drugs that were launched in recent years by VIVUS and Arena Pharmaceuticals (ARNA). The firm keeps an Outperform rating on Orexigen.
September 10, 2014
07:21 EDTAUXLAuxilium sees merger with QLT closing in Q4
Subscribe for More Information
September 9, 2014
17:03 EDTAUXLAuxilium announces corporate restructuring, will cut headcount approximately 30%
Subscribe for More Information
16:55 EDTAUXLAuxilium trading halted, pending news
Subscribe for More Information
12:46 EDTVVUSNovo Nordisk weight loss drug helped people get thinner, Bloomberg reports
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use